Citi is opening a “30-day upside catalyst watch” on Cogent Biosciences (COGT) ahead of topline results from bezuclastinib’s Part 2 registrational portion of the Phase 2 SUMMIT trial in non-advanced systemic mastocytosis patients that are expected in July. The Street has underestimated the potential for bezuclastinib to demonstrate efficacy superiority versus Ayvakit, while overestimating the chances of severe safety signals, argues the analyst, who has a Buy rating and $15 price target on Cogent shares and views the risk/reward setup as “skewed highly positively.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Secures $400M Debt Financing Facility
- Cogent Biosciences secures up to $400M in non-dilutive financing
- Cogent Biosciences Approves Officer Exculpation Amendment
- Cogent Biosciences price target raised to $25 from $21 at JPMorgan
- Cogent Biosciences: Strong Financial Management and Promising Clinical Trials Support Buy Rating